Abstract
Suppression of cell proliferation by targeting mitosis is one potential cancer intervention. A number of existing chemotherapy drugs disrupt mitosis by targeting microtubule dynamics. While efficacious, these drugs have limitations, i.e. neuropathy, unpredictability and development of resistance. In order to overcome these issues, a great deal of effort has been spent exploring novel mitotic targets including Polo-like kinase 1, Aurora kinases, Mps1, Cenp-E and KSP/Eg5. Here we summarize the latest developments in the discovery and clinical evaluation of new mitotic drug targets.
MeSH terms
-
Anticarcinogenic Agents / therapeutic use*
-
Aurora Kinases / metabolism
-
Cell Cycle Proteins / metabolism
-
Cell Proliferation / drug effects
-
Chromosomal Proteins, Non-Histone / metabolism
-
Humans
-
Kinesins / metabolism
-
Mitosis / drug effects
-
Mitosis / genetics*
-
Molecular Targeted Therapy*
-
Polo-Like Kinase 1
-
Protein Serine-Threonine Kinases / metabolism
-
Protein-Tyrosine Kinases / metabolism
-
Proto-Oncogene Proteins / metabolism
Substances
-
Anticarcinogenic Agents
-
Cell Cycle Proteins
-
Chromosomal Proteins, Non-Histone
-
KIF11 protein, human
-
Proto-Oncogene Proteins
-
centromere protein E
-
Protein-Tyrosine Kinases
-
Aurora Kinases
-
Protein Serine-Threonine Kinases
-
TTK protein, human
-
Kinesins